Topcon Medical Systems, Inc.   Report issue

For profit Phase 3
Founded: Oakland NJ United States (1970)
Status: No NME R&D (1970)

Organization Overview

First Clinical Trial
2010
NCT01190306
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

riboflavin (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dilatation, Pathologic (Phase 3)

Keratoconus (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1